Four-year Overall Survival Follow-Up and Dynamic EBV Titer Analysis of Toripalimab Versus Placebo in Combination with Gemcitabine and Cisplatin As First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (r/m NPC).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined